Xeris Biopharma Holdings (XERS) Change in Acquisitions & Divestments (2020 - 2024)

Xeris Biopharma Holdings (XERS) has reported Change in Acquisitions & Divestments for 5 consecutive years, with $10.2 million the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Change in Acquisitions & Divestments fell 31.76% year-over-year to $10.2 million; the trailing twelve-month figure through Sep 2025 stood at $10.2 million (down 77.25% YoY), and the FY2024 full-year result was $40.2 million, up 0.59% from the prior year.
• Change in Acquisitions & Divestments declined to $10.2 million in Q4 2024 per XERS's latest filing, from $15.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $34.6 million in Q1 2021 and bottomed at $5.0 million in Q1 2024.
• Historically, Change in Acquisitions & Divestments has averaged $14.8 million across 5 years, with a median of $11.3 million in 2021.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments plunged 80.66% in 2022, then surged 117.86% in 2023.
• Over 5 years, Change in Acquisitions & Divestments stood at $17.8 million in 2020, then slumped by 41.14% to $10.5 million in 2021, then decreased by 11.43% to $9.3 million in 2022, then surged by 61.29% to $15.0 million in 2023, then slumped by 31.76% to $10.2 million in 2024.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $10.2 million, $15.0 million, and $10.0 million for Q4 2024, Q3 2024, and Q2 2024 respectively.